GE Healthcare has announced its intention to invest $20m in radical
new technology, which will allow laboratory research results to be
transmitted and shared amongst doctors worldwide setting to define
a new age in patient care.
Two products aimed at enhancing the efficiency of process
development in biopharmaceutical manufacturing are the latest
offerings from GE Healthcare, the UK-based medical technology and
GE Healthcare has reported its fourth quarter and full year
financial results in a tough 12 months that have seen the
laboratory imaging and diagnostics company feel the full force of
US Government regulatory pressure.
GE Healthcare and Novavax have a vision - a state-of-the-art
pandemic influenza vaccine manufacturing facility solution with the
ability to produce vaccines quickly, which can be marketed as a
product to international countries.